Free Trial
NASDAQ:ERNA

Ernexa Therapeutics (ERNA) Stock Price, News & Analysis

Ernexa Therapeutics logo
$1.96 -0.02 (-1.01%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$1.98 +0.02 (+0.82%)
As of 07/11/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ernexa Therapeutics Stock (NASDAQ:ERNA)

Key Stats

Today's Range
$1.94
$1.99
50-Day Range
$1.82
$3.72
52-Week Range
$1.75
$39.38
Volume
15,939 shs
Average Volume
199,758 shs
Market Capitalization
$14.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ernexa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

ERNA MarketRank™: 

Ernexa Therapeutics scored higher than 11% of companies evaluated by MarketBeat, and ranked 897th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ernexa Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ernexa Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ernexa Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ernexa Therapeutics has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ernexa Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.33% of the float of Ernexa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ernexa Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ernexa Therapeutics has recently increased by 16.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ernexa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Ernexa Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.33% of the float of Ernexa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Ernexa Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ernexa Therapeutics has recently increased by 16.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Ernexa Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Ernexa Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Ernexa Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Ernexa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ernexa Therapeutics' insider trading history.
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ERNA Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Headlines

ERNA Stock Analysis - Frequently Asked Questions

Ernexa Therapeutics' stock was trading at $4.41 at the beginning of the year. Since then, ERNA stock has decreased by 55.6% and is now trading at $1.96.

Ernexa Therapeutics Inc. (NASDAQ:ERNA) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($73.80) earnings per share for the quarter. The company had revenue of $0.49 million for the quarter.

Ernexa Therapeutics's stock reverse split on Thursday, June 12th 2025.The 1-15 reverse split was announced on Tuesday, June 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

Last Earnings
11/12/2024
Today
7/13/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERNA
CIK
748592
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($8.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.54 million
Net Margins
-7,652.75%
Pretax Margin
-8,609.35%
Return on Equity
N/A
Return on Assets
-285.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$580 thousand
Price / Sales
24.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
3.92

Miscellaneous

Outstanding Shares
7,360,000
Free Float
7,034,000
Market Cap
$14.43 million
Optionable
No Data
Beta
5.30
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ERNA) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners